Monitor for the formation of the Aetherium Entity and closing of the transaction within 30 days. The milestone equity structure creates significant future dilution risk, especially if revenue targets are met. The planned JV with GloMed and $3M call option could be a catalyst if announced, but remains unconfirmed.
Price Chart
Executive Summary
Totaligent has entered into a definitive agreement with Ivan Klarich to acquire Aetherium Medical's intangible assets—including trade secrets, business relationships, and distribution rights—through a non-cash equity transaction. Klarich will receive milestone-based equity, starting with a 10% fully diluted stake upon closing, and be appointed President and board member. The deal is structured to integrate into a future joint venture with GloMed Solutions, though that JV is not a condition to closing.
Key Financial Metrics
Key Facts
- Acquisition of Aetherium Medical's intangible assets (trade secrets, relationships, distribution rights) in exchange for milestone-based equity
- Ivan Klarich to receive 10% fully diluted equity upon closing, with additional tranches tied to JV formation, revenue targets, and IPO
- Klarich appointed President and board member effective immediately
- No cash consideration; transaction structured as tax-free contribution under Section 351
- Separate joint venture with GloMed Solutions is planned but not a condition to closing
- Aetherium platform reportedly generated $10M annual revenue for over 15 years
Financial Impact
Non-cash transaction. Initial 10% equity issuance to Klarich upon closing, with up to 38.26% total dilution upon IPO. No disclosed transaction value.
Risk Factors
- High future dilution from milestone equity (up to 38.26% total)
- Dependence on unproven joint venture with GloMed for value realization
- Founder Don Heath receives no compensation despite 15-year $10M revenue business
- Company's financial instability with going concern doubts and salary reductions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-002227 |
| Document: totaligent_8k.htm | 0001477932-26-002227 |
| Document: 0001477932-26-002227-index-headers.html | 0001477932-26-002227 |
| Document: 0001477932-26-002227-index.html | 0001477932-26-002227 |
| Document: 0001477932-26-002227.txt | 0001477932-26-002227 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 15, 2026 27w ago | 8-K | $0.0150 $0.007000 | ▼ −53.33% | ▼ −61.47% | $0.006000 (−60.00%) |
Feb 25, 2026 34w ago | 8-K | $0.0130 $0.0220 | ▲ +69.23% | ▲ +62.28% | $0.006000 (−53.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers